NEWS & EVENTS

The MSA encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU.

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:

Catalent announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.

Catalent today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany.

Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials.

The 2023 Corporate Responsibility Report highlights progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.

Catalent and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

These upgrades, including the addition of capacity for both development and commercial spray drying, now position Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.

The company also committed to engaging with its suppliers such that 70% of their emissions will have reduction goals aligned with science-based targets by the end of fiscal 2028.